TriSalus Life Sciences (NASDAQ:TLSI) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of TriSalus Life Sciences (NASDAQ:TLSI) from a sell rating to a hold rating in a research report sent to investors on Sunday morning.

Several other equities research analysts also recently commented on TLSI. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Friday, August 7th. Lake Street Capital reduced their price target on shares of TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, May 13th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $7.50.

TriSalus Life Sciences Stock Performance

Shares of TLSI stock opened at $5.27 on Friday. The company has a debt-to-equity ratio of 5.05, a current ratio of 5.35 and a quick ratio of 4.97. The stock has a market cap of $324.53 million, a PE ratio of -4.05 and a beta of 0.43. The stock has a 50-day moving average of $4.58 and a 200-day moving average of $4.31. TriSalus Life Sciences has a one year low of $2.20 and a one year high of $7.95.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.16) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.16). The firm had revenue of $11.41 million during the quarter, compared to analyst estimates of $10.27 million.

Institutional Investors Weigh In On TriSalus Life Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. Cura Wealth Advisors LLC bought a new position in shares of TriSalus Life Sciences during the 2nd quarter worth approximately $36,000. JPMorgan Chase & Co. lifted its position in shares of TriSalus Life Sciences by 35,804.8% in the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock worth $41,000 after purchasing an additional 7,519 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of TriSalus Life Sciences in the second quarter worth $47,000. Invesco Ltd. acquired a new position in TriSalus Life Sciences during the fourth quarter worth $72,000. Finally, Abel Hall LLC acquired a new position in TriSalus Life Sciences during the fourth quarter worth $73,000. Institutional investors and hedge funds own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.